143 related articles for article (PubMed ID: 16213711)
1. Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.
Shi Y; Zhang J; Stein PD; Shi M; O'Connor SP; Bisaha SN; Li C; Atwal KS; Bisacchi GS; Sitkoff D; Pudzianowski AT; Liu EC; Hartl KS; Seiler SM; Youssef S; Steinbacher TE; Schumacher WA; Rendina AR; Bozarth JM; Peterson TL; Zhang G; Zahler R
Bioorg Med Chem Lett; 2005 Dec; 15(24):5453-8. PubMed ID: 16213711
[TBL] [Abstract][Full Text] [Related]
2. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.
Shi Y; Zhang J; Shi M; O'Connor SP; Bisaha SN; Li C; Sitkoff D; Pudzianowski AT; Chong S; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2009 Aug; 19(15):4034-41. PubMed ID: 19541481
[TBL] [Abstract][Full Text] [Related]
3. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
[TBL] [Abstract][Full Text] [Related]
4. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
[TBL] [Abstract][Full Text] [Related]
5. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
6. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
[TBL] [Abstract][Full Text] [Related]
7. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
[TBL] [Abstract][Full Text] [Related]
8. A versatile method for the synthesis of 3-alkoxycarbonyl beta-lactam derivatives.
Jiao L; Zhang Q; Liang Y; Zhang S; Xu J
J Org Chem; 2006 Jan; 71(2):815-8. PubMed ID: 16409001
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Hase Y; Uchida I; Aisaka K; Katoh S; Cho H
J Med Chem; 2005 May; 48(10):3586-604. PubMed ID: 15887966
[TBL] [Abstract][Full Text] [Related]
11. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
Koshio H; Hirayama F; Ishihara T; Shiraki R; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Kaku S; Katayama N; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2005 Feb; 13(4):1305-23. PubMed ID: 15670939
[TBL] [Abstract][Full Text] [Related]
13. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
[TBL] [Abstract][Full Text] [Related]
14. Cascade reaction of isatins with heterocyclic ketene aminals: synthesis of imidazopyrroloquinoline derivatives.
Yu F; Yan S; Hu L; Wang Y; Lin J
Org Lett; 2011 Sep; 13(18):4782-5. PubMed ID: 21848302
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric synthesis of anticancer beta-lactams via Staudinger reaction: utilization of chiral ketene from carbohydrate.
Banik BK; Banik I; Becker FF
Eur J Med Chem; 2010 Feb; 45(2):846-8. PubMed ID: 19962794
[TBL] [Abstract][Full Text] [Related]
16. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
17. Selective and dual action orally active inhibitors of thrombin and factor Xa.
Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.
Zhang P; Bao L; Zuckett JF; Jia ZJ; Woolfrey J; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2004 Feb; 14(4):989-93. PubMed ID: 15013007
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.
Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Uchida I; Aisaka K; Hase Y; Katoh S; Cho H
Bioorg Med Chem Lett; 2005 Jan; 15(1):185-9. PubMed ID: 15582437
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
